Search Results for: covid-19
Articles
IsoPlexis’ Immune Monitoring Helps Identify Early Factors of Long COVID in Cell Publication February 10, 2022
IsoPlexis Corporation recently announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle...CureVac Doses First Participant in Phase 1 Study With Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration With GSK February 10, 2022
CureVac N.V. recently announced it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation...Xanadu Bio Obtains Licenses & Options to Novel Platform Technologies From Yale University to Develop Intranasal SARS CoV-2 mRNA Vaccine Booster February 8, 2022
Xanadu Bio recently announced a broad exclusive license agreement from Yale University for a next-generation polymeric nanoparticle delivery platform known as PACE. Additionally, the company has executed….
Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial February 8, 2022
Ocuphire Pharma, Inc. recently announced it has completed enrollment in MIRA-3, the second Phase 3 FDA registration trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically….
CDMO INNOVATION - How a Global CDMO Puts Innovation at the Forefront of its Business Strategy February 7, 2022
Kai Vogt, Senior Vice President Corporate Development/Legal/Corporate Compliance/IT, Vetter, explains how a global CDMO puts innovation at the forefront of its business strategy.
Valneva & Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate February 7, 2022
Valneva SE and Pfizer Inc. recently reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results….
Pardes Biosciences Announces FDA Clearance of IND Application for Oral Antiviral Drug Candidate for the Treatment & Prevention of SARS-CoV-2 Infections February 3, 2022
Pardes Biosciences, Inc. recently announced its Investigational New Drug (IND) application for PBI-0451 has been cleared by the US FDA....Arch Scientists Publish Data on the Mechanism of Action & Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury February 3, 2022
Arch Biopartners Inc. recently announced a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their...Veru Enters Clinical Trial Collaboration & Supply Agreement With Eli Lilly & Company February 1, 2022
Veru Inc. recently announced it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company. The objective of the collaboration is to evaluate the efficacy and safety of….
Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 With In-Process Vaccine Candidate January 31, 2022
Celsion Corporation recently announced it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge study with Celsion’s DNA-based approach for….
Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder January 27, 2022
Yamo Pharmaceuticals recently announced the first patient has been treated in a Phase 2 study of L1-79 in adolescents and...PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine January 27, 2022
PDS Biotechnology Corporation recently announced preclinical data for its universal flu vaccine, which was shown to be effective against….
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001 January 20, 2022
BetterLife Pharma Inc. recently announced it has received a written response from the US FDA to its pre-investigational new drug...BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect & Pharmacokinetics Data for BETR-001 January 18, 2022
BetterLife Pharma Inc. recently announced it has obtained positive results from an in vivo oral bioavailability and food-effect pharmacokinetic (PK)...SPECIAL FEATURE - Analytical Testing Trends in 2022 January 17, 2022
Contributor Cindy H. Dubin reports on the innovative technologies and techniques that several leading outsourcing providers currently offer for both small and large molecules.
FORMULATION FORUM - Formulation & Process of Lipid Nanoparticles for Delivery of Small Molecules & Biologicals January 17, 2022
Jim Huang, PhD, explains how recently, lipid nanoparticles have emerged as a drug delivery system for biologicals, especially for the COVID-19 mRNA vaccines in which LNPs play a vital role in transporting mRNA into the target cells.
ORGAN-ON-A-CHIP - A Novel Way to Accurately Test Delivery of Non-Standard Formulations January 17, 2022
David Hughes, PhD, says ultimately, the goal of OOC technology is to improve the translatability of data between the lab and the clinic. Through a lung-on-a-chip approach, it is possible to recreate the histoarchitecture, phenotype, and function of bronchial and alveolar areas of the lung.
EXOSOMES - The Next Evolution in Therapy Delivery Beyond the Cell Membrane: The Promise of Exosomes January 17, 2022
Linda Marbán, PhD, says perhaps the best way to get past the cell membrane is to deliver contents the same way that cells send information to each other. And that is by the exosome, which in the case of targeted therapy delivery, has been identified as an alternative that shows powerful promise.
Clinical Trial Begins in the UK to Investigate 3-in-1 High Blood Pressure Pill January 17, 2022
George Medicines recently announced its proprietary triple low-dose combination pill, GMRx2, will be trialed in UK patients with high blood...EXECUTIVE INTERVIEW - GATC Health & Liquid Biosciences: Faster, Cheaper, More Effective Drug Discovery January 14, 2022
Ian Jenkins, Director of Science, and Jeff Moses, CMO at GATC Health, discuss the combined benefits of their MAT platform and Liquid Biosciences’ Emerge mathematical evolution platform to help identify the right biology sooner and focus on a smaller set of potential compounds early in the pre-clinical development process to enable pharma companies to develop drugs with more efficiency and a higher success rate.
